Skip to main content

Table 1 Summary of the clinicopathological parameters of gastric cancer according to the expression of SOX2 and CDX2

From: Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome

  SOX2 CDX2
  Negative Positive   Negative Positive  
  N % N % p N % N % p
Age, years1           
  Mean ± SD 65.8 ± 12.7 63.4 ± 13.5 0.2 64.1 ± 13.6 65.2 ± 12.6 0.6
  Median (Range) 69 (34-85) 66.5 (24-89)   69 (24-89) 67 (36-89)  
Sex1           
  Male 52 41.9 72 58.1 0.02 75 60.5 49 39.5 0.1
  Female 45 58.4 32 41.6 38 49.4 39 50.6
TNM stage2           
  I/II 35 54.7 29 45.3 0.09 26 40.6 38 59.4 0.002
  III/IV 59 44.7 73 55.3 83 62.9 49 37.1
T stage3           
  T1/T2 22 62.9 13 37.1 0.03 13 37.1 22 62.9 0.007
  T3/T4 75 45.5 90 54.5 99 60.0 66 40.0
N stage1           
  N0 28 62.2 17 37.8 0.03 20 44.4 25 55.6 0.07
  N+ 69 44.2 87 55.8 93 59.6 63 40.4
Margins4           
  R0 85 47.5 94 52.5 0.5 98 54.7 81 45.3 0.2
  R1 11 55.0 9 45.0 14 70.0 6 30.0
Vascular invasion4           
  Negative 39 55.7 31 44.3 0.1 37 52.9 33 47.1 0.5
  Positive 57 44.2 72 55.8 75 58.1 54 41.9
Láuren5           
  Intestinal 44 49.4 45 50.6 0.9 45 50.6 44 49.4 0.3
  Diffuse 20 48.8 21 51.2 26 63.4 15 36.6
  Unclassified 31 46.3 36 53.7 40 59.7 27 40.3
Ming6           
  Expansive 32 53.3 28 46.7 0.5 28 46.7 32 53.3 0.1
  Infiltrative 60 45.8 71 54.2 81 61.8 50 38.2
  Unclassified 2 66.7 1 33.3 1 33.3 2 66.7
SOX21           
  Negative       58 59.8 39 40.2 0.3
  Positive       55 52.9 49 47.1
CDX21           
  Negative 58 51.3 55 48.7 0.3      
  Positive 39 44.3 49 55.7      
MUC5AC1           
  Negative 39 44.8 48 55.2 0.4 42 48.3 45 51.7 0.05
  Positive 58 51.3 55 48.7 70 61.9 43 38.1
MUC21           
  Negative 69 48.6 73 51.4 0.9 84 52.2 58 40.8 0.1
  Positive 27 48.2 29 51.8   26 46.4 30 53.6  
  1. 1N = 201; 2N = 196; 3N = 200; 4N = 199; 5N = 197; 6N = 194.
\